Screening of antimalarial drugs: An overview

Indian Journal of Pharmacology

Volumn 38, Issue 1, 2006, Pages 5-12

  Kalra, B S ^a   Chawla, S ^a   Gupta, P ^a   Valecha, N ^b  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

Author keywords

Hypoxanthine uptake; Plasmodium berghei; Primate model; Rodent malaria model

Indexed keywords

ACTINONIN; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; ATOVAQUONE; CHLOROQUINE; CHLORPROGUANIL; CLINDAMYCIN; DAPSONE; FLUOROOROTIC ACID; FOSMIDOMYCIN; GELDANAMYCIN; GOSSYPOL DERIVATIVE; HEXOSE; HYPOXANTHINE; MEFLOQUINE; OXINDOLE; PEROXIDE; PROGUANIL; PROTEINASE INHIBITOR; PYRIMETHAMINE; QUININE; QUINOLINE DERIVATIVE; SULFADOXINE; TETRACYCLINE DERIVATIVE; THIOLACTOMYCIN; TRICLOSAN;

DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; GIEMSA STAIN; IN VITRO STUDY; IN VIVO STUDY; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 33344474102     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.19846     Document Type: Review

References (53)

1. Tracy JW, Webster LT Jr. Drugs used in the chemotherapy of protozoal infections. In: Hardman JG, Limbird LE, editors. The Pharmacological basis of Therapeutics. New York: McGraw-Hill; 2001.
2. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science 1976;193:673-5.
3. Fidock DA, Rosenthal PJ, Croft SL, Nwaka S. Antimalarial drug discovery: Efficacy models for compound screening (supplementary document). Switzerland. Available from: http://www.mmv.org/filesUpld/164.pdf
4. Fidock DA, Rosenthal PJ, Croft SL, Nwaka S. Antimalarial drug discovery: Efficacy models for compound screening. Nat Rev Drug Discov 2004;3:509-20.
5. Desjardins RE. In vitro techniques for antimalarial development and evaluation. In: W.Peters and W.H.G. Richards, editors. Handbook of Experimental Pharmacology. Germany: Springer-Verlag;1984.p179-200
6. Makler MT, Hinrichs DJ. Measurement of the lactate dehydrogenase activity of plasmodium falciparum as an assessment of parasitemia. Am J Trop Med Hyg 1993;48:205-10.
7. Berenbaun MC. A method for testing synergy with any number of agents. J Infect Dis 1978;137:122-30.
8. Ohrt C, Willingmyre CD, Lee P, Knirsh C, Milhous W. Assessment of azithromycin in combination with other antimalarial drugs against plasmodium in vitro. Antimicrob Agents Chemother 2002;46:2518-24.
9. Carfield CJ, Podney M, Gutteridge WE. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 1995;80:373-81.
10. WHO.Roll back Malaria Department. c2004; [cited 2005 May 6]. Available from: http://www.who.int/malaria/resistance.
11. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellens TE. Pyrimethamine and proguanil resistance conferring mutations in Plasmodium falciparum dihydrofolate reductase: PCR method for surveillance in Africa. Am J Trop Med Hyg 1995;52:565-8.
12. Plowe CV, Djimde A, Wellens TE. Community Pyrimethamine Sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali. A model for deterring resistance. Am J Trop Med Hyg 1996;55:467-71.
13. Ager AL Jr. Rodent malaria models. In: Peters W, Richards WHG, editors. Handbook of Experimental Pharmacology. Germany: Springer-Verlag; 1984.
14. Peters W and Robinson B.L. In: Zak O, Sande M, editors. Handbook of animal models of infection. Londen: Academia;1999.
15. Wengelnik K, Vidal V, Ancelin ML, Cathiard AM, Morgat JL, Kocken CH, et al. A class of potent antimalarials and their specific accumulation in infected erythrocytes.Science. 2002;295:1311-4.
16. Moreno A, Badell E, Rooijen NV, Druilhe P. Human malaria in immunocompromised mice: New in vivo model for chemotherapy studies. Antimicrob Agents Chemother 2001;45:1847-53.
17. Richards WHG. Use of avian malaria (in vivo). In: Peters W, Richards WHG, editors. Handbook of Experimental Pharmacology. Germany: Springer-Verlag;1984.
18. Baranger P, Filer MK. Del'action protectrice de colliers dans la malaria aviaire. Essaid'ethrographie experimentale. Acta Trop 1953;10:69-72.
19. Peters W. Techniques of drug evaluation 1: primary screening. In: Chemotherapy and drug resistance in Malaria. Florida: Academic Press;1987.
20. Stowers AW, Miller LH. Are trials in new world monkey on the critical path for blood stage malaria vaccine development? Trends in parasitology 2001;17:415-9.
21. MVT. Malaria vaccine trials, University of Oxford, The Wellcome Trust. Available from http://www.malaria-vaccines-org.uk.html
22. Ballon WR, Herrera MA, Caruca D, Richei TL, Corradin G, Diggs C, et al. Uptake on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 2004;71:239-47.
23. Nzila AM. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan. Plasmodium falciparum. J Infect Dis 2000;181:2023-8.
24. Mutabingwa T. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 2001;358:1218-23.
25. Jiang L, Lee PC, White J, Rathod PK. Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum. Antimicrob Agents Chemother 2000;44:1047-50.
26. Razakantoanina V, Nguyen Kim PP, Jaureguiberry G. Antimalarial activity of new gossypol derivatives. Parasitol Res 2000;86:665-8.
27. Bracchi-Ricard V. Characterization of an eukaryotic peptide deformylase from Plasmodium falciparum. Arch Biochem Biophys 2001;396:162-70.
28. Banumathy G, Singh V, Pavithra SR, Tatu U. Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes. J Biol Chem 2003;278:18336-45.
29. Davioud-Charvet E. A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline. J Med Chem 2001;44:4268-76.
30. Woodard CL. Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases. J Med Chem 2003;46;3877-82.
31. Eckstein-Ludwig U. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003;424;957-61.
32. Roggero R, Zufferey R, Nastase M, Richier E, Calas M, Vial H, et al. Unraveling the mode of action of the antimalarial choline analog G25 in plasmodium and yeast . Antimicrob Agents Chemother 2004;48:2816-24.
33. GeroAM. New malaria chemotherapy developed by utilization of a unique parasite transport system. Curr Pharm Des 2003;9:867-77.
34. Joet T, Eckstein-Ludwig U, Morin C, Krishna S. Validation of the hexose transporter of Plasmodium falciparum as a novel drug target. Proc Natl Acad Sci 2003;100:7476-9.
35. De D, Krogstad FM, Byers LD, Krogstad DJ. Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines. J Med Chem 1998;41:4918-26.
36. Stocks PA. Novel short chain chloroquine analogues retain activity against chloroquine resistant K1 Plasmodium falciparum. J Med Chem 2002;45:4975-83.
37. Francis SE. Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J 1994;13:306-17.
38. Haque TS. Potent, low-molecular-weight nonpeptide inhibitors of malarial aspartyl protease plasmepsin II. J Med Chem 1999;42:1428-40.
39. Rosenthal PJ. In Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery. Rosenthal PJ, editor. Humana, Totawa: New Jersey; 2001.
40. Shenai BR. Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones. Antimicrob Agents Chemother 2003;47:154-60.
41. Vennerstrom JL. Synthesis and antimalarial activity of sixteen dispiro-1, 2, 4, 5-tetraoxanes: Alkyl-substituted 7, 8, 15, 16-tetraoxadispiro [5.2.5.2] hexadecanes. J Med Chem 2000;43:2753-8.
42. Borstnik K, Paik IH, Posner GH. Malaria: New chemotherapeutic peroxide drugs. Mini Rev Med Chem 2002;2:573-83.
43. Vaidya AB. In Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery. Rosenthal PJ, editor. Humana, Totowa: New Jersey; 2001.
44. Clough B, Wilson RJM. In Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery. Rosenthal PJ, editor. Humana, Totawa: New Jersey; 2001.
45. Ralph SA, D'Ombrain MC, McFadden GI. The apicoplast as an antimalarial drug target. Drug Resist Update 2001;4:145-51.
46. Surolia N, Surolia A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nature Med 2001;7:167-73.
47. Perozzo R. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl ACP reductase. J Biol Chem 2002;277:13106-14.
48. McLeod R. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int J Parasitol 2001;31:109-13.
49. Jomaa H. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 1999;285:1573-6.
50. Chakrabarti D. Protein farnesyltransferase and protein prenylation in Plasmodium falciparum. J Biol Chem 2002;277:42066-73.
51. Ohkanda J. Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity. Bioorg Med Chem Lett 2001;11:761-4.
52. Rosenthal PJ. In Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery. Rosenthal PJ, editor. Humana, Totawa: New Jersey; 2001.
53. Blackman MJ. Proteases involved in erythrocyte invasion by the malaria parasite: function and potential as chemotherapeutic targets. Curr Drug Targets 2000;1:59-83.